Nvidia and Eli Lilly commit up to $1B to AI drug discovery lab

Nvidia’s newest lab partner isn’t a chipmaker or a cloud giant. It’s a drugmaker. On January 12, 2026, Nvidia and Eli Lilly announced plans to co-invest up to $1 billion over the next five years in an AI co-innovation lab in the San Francisco Bay Area. The goal is to use AI to change how new medicines are discovered and how biomedical research gets done. The headline figure grabs attention. The structure matters more. This is a joint commitment from two companies, and “up to” signals a ceiling rather than a check already cashed. What the money is supposed to buy The core idea is proximity. Teams from both companies will work in the same space instead of trading emails across organizational lines. Those co-located teams plan to generate large datasets. They will use that data to train foundation models for biology and chemistry. A foundation model is a large AI system trained on broad data and then adapted for specific jobs. ChatGPT learned language. These models are meant to learn molecules, proteins and the chemistry that connects them. The training will run through Nvidia’s BioNeMo platform. It will also use Nvidia’s upcoming Vera Rubin architecture, the chip design that follows ...